Fluidigm upgraded to Outperform from Market Perform at Leerink

theflyonthewall.com

Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.

Rates

View Comments (0)